Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Psychopharmacology
  4. Volume 12, Issue 1
  5. Article
Volume 12, Issue 1
  • ISSN: 2211-5560
  • E-ISSN: 2211-5579

Abstract

Depression is one of the most challenging diseases for society to treat. It is a highly prevalent and disabling illness in the general population. Affective disorders are characterised by depressed mood, diminished interest and pleasure, feelings of guilt or poor self-worth, sleep or food difficulties, decreased energy, and impaired attention. This manuscript will look at depression from a behavioural analytic perspective. The pathogenesis of major depressive disorder is poorly understood. Several lines of experimental and clinical evidence, however, show that the therapeutic effect of most antidepressant drugs is related to an increase in 5-HT-mediated neurotransmission. Alternative techniques, however, are employed to obtain this net effect. A better understanding of the neurological mechanism underpinning antidepressant drugs' delayed onset of action has resulted in the development of ways to accelerate antidepressant responses, which are discussed further below. Many antidepressant medications on the market today are beneficial, but they come with many downsides, including unpleasant side effects, potential interactions, and a low response rate. Natural drugs, on the other hand, are extremely effective, have a low risk, and a limited amount of side effects, which are covered briefly in this paper. Alternative modalities of administration have received a lot of attention in recent decades as a complement to approved prescription pharmaceuticals, especially for people who cannot tolerate oral or parenteral methods. The most promising non-invasive systemic delivery techniques are transdermal and transbronchial administration, and these are the focus of this research.

© 2023 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpsp/10.2174/2211556011666230707122341
2023-07-13
2025-03-16

  • From This Site

    /content/journals/cpsp/10.2174/2211556011666230707122341
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SrivastavaS BohraN BhatiaMS Depression in women in Indian context.Indian J Psychiatry2015576)(S223910.4103/0019‑5545.16148526330641
     [Google Scholar]
  2. AnismanH. ZacharkoR.M. Depression: The predisposing influence of stress. Behavioral and Brain Sciences.Behav. Brain Sci.198251899910.1017/S0140525X00010633
     [Google Scholar]
  3. ChuangC.Y. ShiY.C. YouH.P. LoY.H. PanT.M. Antidepressant effect of GABA-rich monascus-fermented product on forced swimming rat model.J. Agric. Food Chem.20115973027303410.1021/jf104239m 21375324
     [Google Scholar]
  4. XuQ. PanY. YiL.T. Antidepressant-like effects of psoralen isolated from the seeds of Psoralea corylifolia in the mouse forced swimming test.Biol. Pharm. Bull.20083161109111410.1248/bpb.31.1109 18520040
     [Google Scholar]
  5. MukherjeeP.K. KumarV. MalM. HoughtonP.J. Acorus calamus: Scientific validation of ayurvedic tradition from natural resources.Pharm. Biol.200745865166610.1080/13880200701538724
     [Google Scholar]
  6. LewisG. Diagnostic and Statistical Manual of Mental Disorders.American Psychiatric Association199688610.1017/S0033291700035765
     [Google Scholar]
  7. KellerM.B. HirschfeldR.M.A. HanksD. Double depression: A distinctive subtype of unipolar depression.J. Affect. Disord.1997451-2657310.1016/S0165‑0327(97)00060‑8 9268776
     [Google Scholar]
  8. Ashok KumarB.S. LakshmanK. VelmuruganC. SridharS.M. GopisettyS. Antidepressant activity of methanolic extract of amaranthus spinosus.Basic Clin. Neurosci.2014511117 25436078
     [Google Scholar]
  9. BadheS.R. BadheR.V. GhaisasM.M. ChopadeV.V. DeshpandeA.D. Evaluations of antidepressant activity of Anacyclus pyrethrum root extract.Int J Green Pharm2010427910.4103/0973‑8258.63880
     [Google Scholar]
  10. ShalamM.D. ShantakumarS.M. NarasuM.L. Pharmacological and biochemical evidence for the antidepressant effect of the herbal preparation Trans-01.Indian J. Pharmacol.200739523110.4103/0253‑7613.37273
     [Google Scholar]
  11. NadkarniA.K. Indian Materica Medica.3rd edMumbaiPopular Publication2000Vol. 19798
     [Google Scholar]
  12. WattanathornJ. PangpookiewP. SripanidkulchaiK. MuchimapuraS. SripanidkuchaiB. Evaluation of the anxiolytic and antidepressant effects of alcoholic extract of Kaempferia parviflora in aged rats.Am. J. Agric. Biol. Sci.20072216
     [Google Scholar]
  13. BuchbauerG. JirovetzL. JägerW. DietrichH. PlankC. Aromatherapy: evidence for sedative effects of the essential oil of lavender after inhalation.Z. Naturforsch. C J. Biosci.19914611-121067107210.1515/znc‑1991‑11‑1223 1817516
     [Google Scholar]
  14. LekamgeS. NakachiM. SatoS. ItoK. NomuraS. Alleviation of the acute stress response following mild orange essential oil administration.IEEJ Trans. Electr. Electron. Eng.201712S158S16310.1002/tee.22428
     [Google Scholar]
  15. BuchbauerG. JagerW. JirovetzL. IlmbergerJ. DietrichH. Therapeutic properties of essential oils and fragrances Bioactive volatile compounds from plants.Washington, DCAmerican Chemical Society199315916510.1021/bk‑1993‑0525.ch012
     [Google Scholar]
  16. JawaidT.A. ImamS.A. KamalM.E. Antidepressant activity of methanolic extract of Verbena Officinalis Linn. plant in mice.Asian J. Pharm. Clin. Res.201584308310
     [Google Scholar]
  17. SharmaV.K. ChauhanN.S. LodhiS. SinghaiA.K. Anti-depressant activity of Zizyphus xylopyrus.Int. J. Phytomed.200911121710.5138/ijpm.2009.0975.0185.05788
     [Google Scholar]
  18. PisaniG. FacioniL. FioraniF. PisaniG. Psychosexual problems in menopause.Minerva Ginecol.19985037781 9595919
     [Google Scholar]
  19. KesslerR. McGonagleK.A. SwartzM. BlazerD.G. NelsonC.B. Sex and depression in the National Comorbidity Survey I: Lifetime prevalence, chronicity and recurrence.J. Affect. Disord.1993292-3859610.1016/0165‑0327(93)90026‑G 8300981
     [Google Scholar]
  20. BirkhäuserM. Depression, menopause and estrogens: is there a correlation?Maturitas200241Suppl. 13810.1016/S0378‑5122(02)00009‑9 11955789
     [Google Scholar]
  21. TaylorM. Psychological consequences of surgical menopause.J. Reprod. Med.2001463Suppl.317324 11304879
     [Google Scholar]
  22. NestlerE.J. CarlezonW.A.Jr The mesolimbic dopamine reward circuit in depression.Biol. Psychiatry200659121151115910.1016/j.biopsych.2005.09.018 16566899
     [Google Scholar]
  23. 199510.1176/ajp.152.8.1228
  24. World Health Organization The ICD-10 Classification of mental and behaviour disorder: clinical descriptions and diagnostic guidelines.WHOGeneva1992
     [Google Scholar]
  25. WongM.L. LicinioJ. Research and treatment approaches to depression.Nat. Rev. Neurosci.20012534335110.1038/35072566 11331918
     [Google Scholar]
  26. Diagnostic and statistical manual for mental disorders. 4th ed. DSM-IV. Washington, D.C.: American Psychiatric Press 2000. Available From: https://www.psychiatry.org/psychiatrists/practice/dsm
  27. AshwaniA. PreetiV. Review article a review on pathophysiology.Classification And Longterm Course Of Depression2012339096
     [Google Scholar]
  28. FavaM. KendlerK.S. Major depressive disorder.Neuron200028233534110.1016/S0896‑6273(00)00112‑4 11144343
     [Google Scholar]
  29. AtzoriM. Cuevas-OlguinR. Esquivel-RendonE. Locus ceruleus norepinephrine release: a central regulator of CNS spatio-temporal activation?Front. Synaptic Neurosci.201682510.3389/fnsyn.2016.00025 27616990
     [Google Scholar]
  30. GraceA.A. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression.Nat. Rev. Neurosci.201617852453210.1038/nrn.2016.57 27256556
     [Google Scholar]
  31. StahlS.M. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action.J. Clin. Psychiatry1998594514 9554316
     [Google Scholar]
  32. MaesM. The serotonin hypothesis of depression.In: Psychopharmacology: the fourth generation of progress.199593344
     [Google Scholar]
  33. PerryE.K. MarshallE.F. BlessedG. TomlinsonB.E. PerryR.H. Decreased imipramine binding in the brains of patients with depressive illness.Br. J. Psychiatry1983142218819210.1192/bjp.142.2.188 6839075
     [Google Scholar]
  34. CraddockN. KhodelV. Van EerdeweghP. ReichT. Mathematical limits of multilocus models: The genetic transmission of bipolar disorder.Am. J. Hum. Genet.1995573690702 7668299
     [Google Scholar]
  35. López LeónS. CroesE.A. Sayed-TabatabaeiF.A. ClaesS. BroeckhovenC.V. van DuijnC.M. The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: A meta-analysis.Biol. Psychiatry2005579999100310.1016/j.biopsych.2005.01.030 15860340
     [Google Scholar]
  36. López-LeónS. JanssensA.C.J.W. González-Zuloeta LaddA.M. Meta-analyses of genetic studies on major depressive disorder.Mol. Psychiatry200813877278510.1038/sj.mp.4002088 17938638
     [Google Scholar]
  37. ThaseM.E. HowlandR.H. Biological processes in depression: An updated review and integration.Handbook of depression. BeckhamE.E. GuilfordLeber WR New York1995213279
     [Google Scholar]
  38. SegerstromS.C. MillerG.E. Psychological stress and the human immune system: A meta-analytic study of 30 years of inquiry.Psychol. Bull.2004130460163010.1037/0033‑2909.130.4.601 15250815
     [Google Scholar]
  39. DinarelloC.A. Role of pro- and anti-inflammatory cytokines during inflammation: Experimental and clinical findings.J. Biol. Regul. Homeost. Agents199711391103 9498158
     [Google Scholar]
  40. SongC. HalbreichU. HanC. LeonardB.E. LuoH. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment.Pharmacopsychiatry200942518218810.1055/s‑0029‑1202263 19724980
     [Google Scholar]
  41. HennF.A. VollmayrB. Neurogenesis and depression: Etiology or epiphenomenon?Biol. Psychiatry200456314615010.1016/j.biopsych.2004.04.011 15271582
     [Google Scholar]
  42. BjørnebekkA. MathéA.A. BrenéS. The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression.Hippocampus200920782082810.1002/hipo.20683 19623606
     [Google Scholar]
  43. HaynesS.N. O’BrienW.H. Functional analysis in behavior therapy.Clin. Psychol. Rev.199010664966810.1016/0272‑7358(90)90074‑K
     [Google Scholar]
  44. HawkinsR.P. Selection of target behaviours. Conceptual foundations of behavioural assessment.New YorkGuilford Press198632938510.1016/S0005‑7894(96)80047‑5
     [Google Scholar]
  45. HanleyG.P. IwataB.A. McCordB.E. Functional analysis of problem behavior: a review.J. Appl. Behav. Anal.200336214718510.1901/jaba.2003.36‑147 12858983
     [Google Scholar]
  46. RennerK.E. Delay of reinforcement: A historical review.Psychol. Bull.196461534136110.1037/h0048335 14146339
     [Google Scholar]
  47. KohlenbergR.J. TsaiM. DougherM.J. The dimensions of clinical behavior analysis.Behav. Anal.199316227128210.1007/BF03392636 22478158
     [Google Scholar]
  48. CookeM.J. WaringW.S. Citalopram and cardiac toxicity.Eur. J. Clin. Pharmacol.201369475576010.1007/s00228‑012‑1408‑1 22996077
     [Google Scholar]
  49. SanchezC. ReinesE.H. MontgomeryS.A. A comparative review of escitalopram, paroxetine, and sertraline.Int. Clin. Psychopharmacol.201429418519610.1097/YIC.0000000000000023 24424469
     [Google Scholar]
  50. AmidfarM. KimY.K. Recent developments on future antidepressant-related serotonin receptors.Curr. Pharm. Des.201824222541254810.2174/1381612824666180803111240 30073919
     [Google Scholar]
  51. LepolaU. WadeA. AndersenH.F. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder.Int. Clin. Psychopharmacol.200419314915510.1097/00004850‑200405000‑00005 15107657
     [Google Scholar]
  52. RobertsonO.D. CoronadoN.G. SethiR. BerkM. DoddS. Putative neuroprotective pharmacotherapies to target the staged progression of mental illness.Early Interv. Psychiatry20191351032104910.1111/eip.12775 30690898
     [Google Scholar]
  53. SaadM.A. El-SaharA.E. SayedR.H. ElbazE.M. HelmyH.S. SenousyM.A. Venlafaxine mitigates depressive-like behavior in ovariectomized rats by activating the EPO/EPOR/JAK2 signaling pathway and increasing the serum estradiol level.Neurotherapeutics201916240441510.1007/s13311‑018‑00680‑6 30361931
     [Google Scholar]
  54. DetkeM.J. WiltseC.G. MallinckrodtC.H. McNamaraR.K. DemitrackM.A. BitterI. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.Eur. Neuropsychopharmacol.200414645747010.1016/j.euroneuro.2004.01.002 15589385
     [Google Scholar]
  55. FredS.M. LaukkanenL. BrunelloC.A. Pharmacologically diverse antidepressants facilitate TRKB receptor activation by disrupting its interaction with the endocytic adaptor complex AP-2.J. Biol. Chem.201929448181501816110.1074/jbc.RA119.008837 31631060
     [Google Scholar]
  56. ZieglerC. DomschkeK. Epigenetic signature of MAOA and MAOB genes in mental disorders.J. Neural Transm.2018125111581158810.1007/s00702‑018‑1929‑6 30242487
     [Google Scholar]
  57. FagioliniA. ComandiniA. Dell’OssoM.C. KasperS. Rediscovering trazodone for the treatment of major depressive disorder.CNS Drugs201226121033104910.1007/s40263‑012‑0010‑5 23192413
     [Google Scholar]
  58. PaccosiS. CresciB. PalaL. RotellaC.M. ParentiA. Obesity therapy: How and why?Curr. Med. Chem.202027217418610.2174/0929867326666190124121725 30678612
     [Google Scholar]
  59. Schwasinger-SchmidtT.E. MacalusoM. Other antidepressants InAntidepressants.ChamSpringer201832535510.1007/164_2018_167
     [Google Scholar]
  60. GillmanP.K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.Br. J. Pharmacol.2007151673774810.1038/sj.bjp.0707253 17471183
     [Google Scholar]
  61. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.Natl Inst Diabetes Digestive Kidney Dis2018
     [Google Scholar]
  62. DerryS. WiffenP.J. AldingtonD. MooreR.A. Nortriptyline for neuropathic pain in adults.Cochrane Database Syst. Rev.201511CD01120910.1002/14651858.cd011209.pub 25569864
     [Google Scholar]
  63. RiedigerC. SchusterT. BarlinnK. MaierS. WeitzJ. SiepmannT. Adverse effects of antidepressants for chronic pain: A systematic review and meta-analysis.Front. Neurol.2017830710.3389/fneur.2017.00307 28769859
     [Google Scholar]
  64. GutmanD.A. GutmanA.R. OwensM.J. NemeroffC.B. Stress neurobiology and corticotropin-releasing factor.Psychiatr. Times2006231091
     [Google Scholar]
  65. ArboreliusL. OwensM.J. PlotskyP.M. NemeroffC.B. The role of corticotropin-releasing factor in depression and anxiety disorders.J. Endocrinol.1999160111210.1677/joe.0.1600001 9854171
     [Google Scholar]
  66. BittencourtJ.C. BenoitR. SawchenkoP.E. Distribution and origins of substance P-immunoreactive projections to the paraventricular and supraoptic nuclei: Partial overlap with ascending catecholaminergic projections.J. Chem. Neuroanat.199141637810.1016/0891‑0618(91)90032‑8 1707281
     [Google Scholar]
  67. CulmanJ. UngerT. Central tachykinins: Mediators of defence reaction and stress reactions.Can. J. Physiol. Pharmacol.199573788589110.1139/y95‑122 8846426
     [Google Scholar]
  68. ArgyropoulosS.V. NuttD.J. Substance P antagonists: Novel agents in the treatment of depression.Expert Opin. Investig. Drugs2000981871187510.1517/13543784.9.8.1871 11060783
     [Google Scholar]
  69. MannJ.J. AaronsS.F. WilnerP.J. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.Arch. Gen. Psychiatry1989461455010.1001/archpsyc.1989.01810010047007 2491941
     [Google Scholar]
  70. WeckerL. JamesS. CopelandN. PachecoM.A. Transdermal selegiline: Targeted effects on monoamine oxidases in the brain.Biol. Psychiatry200354101099110410.1016/S0006‑3223(02)01892‑9 14625153
     [Google Scholar]
  71. DaillyE. ChenuF. RenardC.E. BourinM. Dopamine, depression and antidepressants.Fundam. Clin. Pharmacol.200418660160710.1111/j.1472‑8206.2004.00287.x 15548230
     [Google Scholar]
  72. BeerB. StarkJ. KrieterP. DOV 216,303, a “triple” reuptake inhibitor: Safety, tolerability, and pharmacokinetic profile.J. Clin. Pharmacol.200444121360136710.1177/0091270004269560 15545306
     [Google Scholar]
  73. MaybergH.S. Positron emission tomography imaging in depression: A neural systems perspective.Neuroimaging Clin. N. Am.200313480581510.1016/S1052‑5149(03)00104‑7 15024963
     [Google Scholar]
  74. CosgroveG.R. RauchS.L. Stereotactic cingulotomy.Neurosurg. Clin. N. Am.200314222523510.1016/S1042‑3680(02)00115‑8 12856490
     [Google Scholar]
  75. BakewellC.J. RussoJ. TannerC. AveryD.H. NeumaierJ.F. Comparison of clinical efficacy and side effects for bitemporal and bifrontal electrode placement in electroconvulsive therapy.J. ECT200420314515310.1097/00124509‑200409000‑00005 15342998
     [Google Scholar]
  76. LisanbyS.H. LuberB. SchlaepferT.E. SackeimH.A. Safety and feasibility of magnetic seizure therapy (MST) in major depression: Randomized within-subject comparison with electroconvulsive therapy.Neuropsychopharmacology200328101852186510.1038/sj.npp.1300229 12865903
     [Google Scholar]
  77. DeuschlG. WenzelburgerR. KopperF. VolkmannJ. Deep brain stimulation of the subthalamic nucleus for Parkinson’s disease: A therapy approaching evidence-based standards.J. Neurol.2003250S1i43i4610.1007/s00415‑003‑1109‑8 12761636
     [Google Scholar]
  78. HerzogJ. VolkmannJ. KrackP. Two-year follow-up of subthalamic deep brain stimulation in Parkinson’s disease.Mov. Disord.200318111332133710.1002/mds.10518 14639676
     [Google Scholar]
  79. ParikhS.V. SegalZ.V. GrigoriadisS. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication.J. Affect. Disord.2009117Suppl. 1S15S2510.1016/j.jad.2009.06.042 19682749
     [Google Scholar]
  80. VittenglJ.R. ClarkL.A. JarrettR.B. Continuation-phase cognitive therapy’s effects on remission and recovery from depression.J. Consult. Clin. Psychol.200977236737110.1037/a0015238 19309197
     [Google Scholar]
  81. HollonS.D. DeRubeisR.J. SheltonR.C. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression.Arch. Gen. Psychiatry200562441742210.1001/archpsyc.62.4.417 15809409
     [Google Scholar]
  82. CuijpersP. van StratenA. WarmerdamL. AnderssonG. Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: A meta-analysis.Depress. Anxiety200926327928810.1002/da.20519 19031487
     [Google Scholar]
  83. KesslerD. LewisG. KaurS. Therapist-delivered internet psychotherapy for depression in primary care: A randomised controlled trial.Lancet2009374969062863410.1016/S0140‑6736(09)61257‑5 19700005
     [Google Scholar]
  84. SimonG.E. LudmanE.J. RutterC.M. Incremental benefit and cost of telephone care management and telephone psychotherapy for depression in primary care.Arch. Gen. Psychiatry200966101081108910.1001/archgenpsychiatry.2009.123 19805698
     [Google Scholar]
  85. WeissmanM. MarkowitzJ. Clinician’s quick guide to interpersonal psychotherapy.Oxford University Press200710.1093/med:psych/9780195309416.001.0001
     [Google Scholar]
  86. LutyS.E. CarterJ.D. McKenzieJ.M. Randomised controlled trial of interpersonal psychotherapy and cognitive–behavioural therapy for depression.Br. J. Psychiatry2007190649650210.1192/bjp.bp.106.024729 17541109
     [Google Scholar]
  87. SchrammE. van CalkerD. DykierekP. An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: Acute and long-term results.Am. J. Psychiatry2007164576877710.1176/ajp.2007.164.5.768 17475736
     [Google Scholar]
  88. FrankE. KupferD. BysseD. Randomised trial of weekly, twice-monthly, monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression.Am. J. Psychiatry2007164576176710.1176/ajp.2007.164.5.761 17475735
     [Google Scholar]
  89. PagninD. de QueirozV. PiniS. CassanoG.B. Efficacy of ECT in depression: A meta-analytic review.Focus Am. Psychiatr. Publ.20086115516210.1176/foc.6.1.foc155
     [Google Scholar]
  90. KimD.R. PesiridouA. O’ReardonJ.P. Transcranial magnetic stimulation in the treatment of psychiatric disorders.Curr. Psychiatry Rep.200911644745210.1007/s11920‑009‑0068‑z 19909666
     [Google Scholar]
  91. SlotemaC.W. BlomJ.D. HoekH.W. SommerI.E.C. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders.J. Clin. Psychiatry201071787388410.4088/JCP.08m04872gre 20361902
     [Google Scholar]
  92. GiacobbeP. KennedyS.H. Deep brain stimulation for treatment-resistant depression: A psychiatric perspective.Curr. Psychiatry Rep.20068643744410.1007/s11920‑006‑0048‑5 17094923
     [Google Scholar]
  93. DumanR.S. HeningerG.R. NestlerE.J. A molecular and cellular theory of depression.Arch. Gen. Psychiatry199754759760610.1001/archpsyc.1997.01830190015002 9236543
     [Google Scholar]
  94. DumanR.S. MonteggiaL.M. A neurotrophic model for stress-related mood disorders.Biol. Psychiatry200659121116112710.1016/j.biopsych.2006.02.013 16631126
     [Google Scholar]
  95. EganM.F. KojimaM. CallicottJ.H. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.Cell2003112225726910.1016/S0092‑8674(03)00035‑7 12553913
     [Google Scholar]
  96. ChiaruttiniC. VicarioA. LiZ. Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation.Proc. Natl. Acad. Sci. USA200910638164811648610.1073/pnas.0902833106 19805324
     [Google Scholar]
  97. MachadoD.G. BettioL.E.B. CunhaM.P. Antidepressant-like effect of rutin isolated from the ethanolic extract from Schinus molle L. in mice: Evidence for the involvement of the serotonergic and noradrenergic systems.Eur. J. Pharmacol.20085871-316316810.1016/j.ejphar.2008.03.021 18457827
     [Google Scholar]
  98. FreitasA.E. BudniJ. LobatoK.R. Antidepressant-like action of the ethanolic extract from Tabebuia avellanedae in mice: Evidence for the involvement of the monoaminergic system.Prog. Neuropsychopharmacol. Biol. Psychiatry201034233534310.1016/j.pnpbp.2009.12.010 20026371
     [Google Scholar]
  99. Sánchez-MateoC.C. BonkankaC.X. PradoB. RabanalR.M. Antidepressant activity of some Hypericum reflexum L. fil. extracts in the forced swimming test in mice.J. Ethnopharmacol.2007112111512110.1016/j.jep.2007.02.019 17383128
     [Google Scholar]
  100. SinghG.K. GarabaduD. MuruganandamA.V. JoshiV.K. KrishnamurthyS. Antidepressant activity of Asparagus racemosus in rodent models.Pharmacol. Biochem. Behav.200991328329010.1016/j.pbb.2008.07.010 18692086
     [Google Scholar]
  101. LeeS. KimD.H. LeeC.H. Antidepressant-like activity of the aqueous extract of Allium macrostemon in mice.J. Ethnopharmacol.2010131238639510.1016/j.jep.2010.07.015 20637276
     [Google Scholar]
  102. YiL.T. XuQ. LiY.C. YangL. KongL.D. Antidepressant-like synergism of extracts from magnolia bark and ginger rhizome alone and in combination in mice.Prog. Neuropsychopharmacol. Biol. Psychiatry200933461662410.1016/j.pnpbp.2009.03.001 19285110
     [Google Scholar]
  103. GaldinoP.M. NascimentoM.V.M. SampaioB.L. FerreiraR.N. PaulaJ.R. CostaE.A. Antidepressant-like effect of Lafoensia pacari A. St.-Hil. ethanolic extract and fractions in mice.J. Ethnopharmacol.2009124358158510.1016/j.jep.2009.05.001 19439172
     [Google Scholar]
  104. HattesohlM. FeistelB. SieversH. LehnfeldR. HeggerM. WinterhoffH. Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties.Phytomedicine2008151-221510.1016/j.phymed.2007.11.027 18160026
     [Google Scholar]
  105. CapraJ.C. CunhaM.P. MachadoD.G. Antidepressant-like effect of scopoletin, a coumarin isolated from Polygala sabulosa (Polygalaceae) in mice: Evidence for the involvement of monoaminergic systems.Eur. J. Pharmacol.20106432-323223810.1016/j.ejphar.2010.06.043 20599906
     [Google Scholar]
  106. RodriguesA.L.S. da SilvaG.L. MateussiA.S. Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus.Life Sci.200270121347135810.1016/S0024‑3205(01)01498‑9 11885577
     [Google Scholar]
  107. Guadarrama-CruzG. Alarcon-AguilarF.J. Lezama-VelascoR. Vazquez-PalaciosG. Bonilla-JaimeH. Antidepressant-like effects of Tagetes lucida Cav. in the forced swimming test.J. Ethnopharmacol.2008120227728110.1016/j.jep.2008.08.013 18782612
     [Google Scholar]
  108. MachadoD.G. BettioL.E.B. CunhaM.P. Antidepressant-like effect of the extract of Rosmarinus officinalis in mice: Involvement of the monoaminergic system.Prog. Neuropsychopharmacol. Biol. Psychiatry200933464265010.1016/j.pnpbp.2009.03.004 19286446
     [Google Scholar]
  109. WangY. HanT. ZhuY. Antidepressant properties of bioactive fractions from the extract of Crocus sativus L.J. Nat. Med.2010641243010.1007/s11418‑009‑0360‑6 19787421
     [Google Scholar]
  110. YuZ.F. KongL.D. ChenY. Antidepressant activity of aqueous extracts of Curcuma longa in mice.J. Ethnopharmacol.2002831-216116510.1016/S0378‑8741(02)00211‑8 12413724
     [Google Scholar]
  111. Sánchez-MateoC.C. BonkankaC.X. PradoB. RabanalR.M. Antidepressant properties of some Hypericum canariense L. and Hypericum glandulosum Ait. extracts in the forced swimming test in mice.J. Ethnopharmacol.200597354154710.1016/j.jep.2004.12.019 15740893
     [Google Scholar]
  112. BhattamisraS.K. KhannaV.K. AgrawalA.K. SinghP.N. SinghS.K. Antidepressant activity of standardised extract of Marsilea minuta Linn.J. Ethnopharmacol.20081171515710.1016/j.jep.2008.01.012 18299179
     [Google Scholar]
  113. KwonS. LeeB. KimM. LeeH. ParkH.J. HahmD.H. Antidepressant-like effect of the methanolic extract from Bupleurum falcatum in the tail suspension test.Prog. Neuropsychopharmacol. Biol. Psychiatry201034226527010.1016/j.pnpbp.2009.11.015 19932727
     [Google Scholar]
  114. MaityT.K. MandalS.C. SahaB.P. PalM. Effect of Ocimum sanctum roots extract on swimming performance in mice.Phytother. Res.200014212012110.1002/(SICI)1099‑1573(200003)14:2<120::AID‑PTR557>3.0.CO;2‑0 10685110
     [Google Scholar]
  115. KulkarniS.K. DhirA. On the mechanism of antidepressant-like action of berberine chloride.Eur. J. Pharmacol.20085891-316317210.1016/j.ejphar.2008.05.043 18585703
     [Google Scholar]
  116. SairamK. DorababuM. GoelR.K. BhattacharyaS.K. Antidepressant activity of standardized extract of Bacopa monniera in experimental models of depression in rats.Phytomedicine20029320721110.1078/0944‑7113‑00116 12046860
     [Google Scholar]
  117. YaoC.Y. WangJ. DongD. QianF.G. XieJ. PanS.L. Laetispicine, an amide alkaloid from Piper laetispicum, presents antidepressant and antinociceptive effects in mice.Phytomedicine200916982382910.1016/j.phymed.2009.02.008 19447013
     [Google Scholar]
  118. SakakibaraH. IshidaK. GrundmannO. Antidepressant effect of extracts from Ginkgo biloba leaves in behavioral models.Biol. Pharm. Bull.20062981767177010.1248/bpb.29.1767 16880641
     [Google Scholar]
  119. WinterhoffH. SpenglerB. ChristoffelV. ButterweckV. LöhningA. Cimicifuga extract BNO 1055: reduction of hot flushes and hints on antidepressant activity.Maturitas200344Suppl. 1S51S5810.1016/S0378‑5122(02)00348‑1 12609559
     [Google Scholar]
  120. ZhaoZ. WangW. GuoH. ZhouD. Antidepressant-like effect of liquiritin from Glycyrrhiza uralensis in chronic variable stress induced depression model rats.Behav. Brain Res.2008194110811310.1016/j.bbr.2008.06.030 18655806
     [Google Scholar]
  121. MathiasN.R. HussainM.A. Non-invasive systemic drug delivery: Developability considerations for alternate routes of administration.J. Pharm. Sci.201099112010.1002/jps.21793 19499570
     [Google Scholar]
  122. IbrahimM. Garcia-ContrerasL. Mechanisms of absorption and elimination of drugs administered by inhalation.Ther. Deliv.2013481027104510.4155/tde.13.67 23919477
     [Google Scholar]
  123. BerlinskiA. Assessing new technologies in aerosol medicine: Strengths and limitations.Respir. Care201560683384910.4187/respcare.03551 26070578
     [Google Scholar]
  124. PatelM.M. GoyalB.R. BhadadaS.V. BhattJ.S. AminA.F. Getting into the brain.CNS Drugs2009231355810.2165/0023210‑200923010‑00003 19062774
     [Google Scholar]
  125. VyasT TiwariSB AmijiMM Formulation and physiological factors influencing CNS delivery upon intranasal administration.Crit Rev Ther Drug Carr200623410.1615/CritRevTherDrugCarrierSyst.v23.i4.20
     [Google Scholar]
  126. MillerJ.L. AshfordJ.W. ArcherS.M. RudyA.C. WermelingD.P. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: A pilot pharmacokinetic study.Pharmacotherapy200828787588210.1592/phco.28.7.875 18576902
     [Google Scholar]
  127. ThompsonD. DiMartiniA. Nonenteral routes of administration for psychiatric medications. A literature review.Psychosomatics199940318519210.1016/S0033‑3182(99)71234‑X 10341530
     [Google Scholar]
  128. RobbinsB. ReissR.A. Amitriptyline absorption in a patient with short bowel syndrome.Am. J. Gastroenterol.19999482302230410.1111/j.1572‑0241.1999.01323.x 10445571
     [Google Scholar]
  129. FowlerJ.S. LoganJ. VolkowN.D. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.Neuropsychopharmacology201540365065710.1038/npp.2014.214 25249059
     [Google Scholar]
  130. MotwaniJ.G. LipworthB.J. Clinical pharmacokinetics of drug administered buccally and sublingually.Clin. Pharmacokinet.1991212839410.2165/00003088‑199121020‑00001 1884569
     [Google Scholar]
  131. MarkowitzJ.S. DeVaneC.L. MalcolmR.J. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers.J. Clin. Pharmacol.200646216417110.1177/0091270005283839 16432268
     [Google Scholar]
  132. DouzenisA. MichopoulosI. EconomopoulosT. LykourasL. SoldatosC.R. Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition.Eur. J. Cancer Care200716328929010.1111/j.1365‑2354.2006.00735.x 17508951
     [Google Scholar]
  133. YapR. AkhileswaranR. HengC.P. TanA. HuiD. Comfort care kit: Use of nonoral and nonparenteral rescue medications at home for terminally ill patients with swallowing difficulty.J. Palliat. Med.201417557557810.1089/jpm.2013.0364 24708221
     [Google Scholar]
  134. PakyurekM PasolE Sublingually administered fluoxetine for major depression in medically compromised patients.Am J Psychiatry1999156111833-a
     [Google Scholar]
  135. BernerB. JohnV.A. Pharmacokinetic characterisation of transdermal delivery systems.Clin. Pharmacokinet.199426212113410.2165/00003088‑199426020‑00005 8162656
     [Google Scholar]
  136. ScottM.A. LetrentK.J. HagerK.L. BurchJ.L. Use of transdermal amitriptyline gel in a patient with chronic pain and depression.Pharmacotherapy199919223623910.1592/phco.19.3.236.30922 10030776
     [Google Scholar]
  137. WeilandA. ProtusB. KimbrelJ. GrauerP. HirshJ. Chlorpromazine bioavailability from a topical gel formulation in volunteers.J. Support. Oncol.201311314414810.12788/j.suponc.0010 24400394
     [Google Scholar]
  138. van HoogdalemE.J. de BoerA.G. BreimerD.D. Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs.Clin. Pharmacokinet.1991211112610.2165/00003088‑199121010‑00002 1717195
     [Google Scholar]
  139. MirassouM.M. Rectal antidepressant medication in the treatment of depression.J. Clin. Psychiatry19985912910.4088/JCP.v59n0107a 9491063
     [Google Scholar]
  140. StoreyP. TrumbleM. Rectal doxepin and carbamazepine therapy in patients with cancer.N. Engl. J. Med.1992327181318131910.1056/NEJM199210293271816 1406828
     [Google Scholar]
  141. TeterC.J. PhanK.L. CameronO.G. GuthrieS.K. Relative rectal bioavailability of fluoxetine in normal volunteers.J. Clin. Psychopharmacol.2005251747810.1097/01.jcp.0000150220.46254.b1 15643102
     [Google Scholar]
  142. DalyE.J. SinghJ.B. FedgchinM. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial.JAMA Psychiatry201875213914810.1001/jamapsychiatry.2017.3739 29282469
     [Google Scholar]
  143. GálvezV. LiA. HugginsC. Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial.J. Psychopharmacol.201832439740710.1177/0269881118760660 29542371
     [Google Scholar]
  144. WilkinsonS.T. BallardE.D. BlochM.H. The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis.Am. J. Psychiatry2018175215015810.1176/appi.ajp.2017.17040472 28969441
     [Google Scholar]
  145. SanacoraG. FryeM.A. McDonaldW. A consensus statement on the use of ketamine in the treatment of mood disorders.JAMA Psychiatry201774439940510.1001/jamapsychiatry.2017.0080 28249076
     [Google Scholar]
  146. RosenblatJ.D. McIntyreR.S. Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials.J. Affect. Disord.201822721922510.1016/j.jad.2017.10.042 29102836
     [Google Scholar]
  147. RaisonC.L. RutherfordR.E. WoolwineB.J. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers.JAMA Psychiatry2013701314110.1001/2013.jamapsychiatry.4 22945416
     [Google Scholar]
  148. KöhlerO. BenrosM.E. NordentoftM. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: A systematic review and meta-analysis of randomized clinical trials.JAMA Psychiatry201471121381139110.1001/jamapsychiatry.2014.1611 25322082
     [Google Scholar]
  149. EhrichE. TurncliffR. DuY. Evaluation of opioid modulation in major depressive disorder.Neuropsychopharmacology20154061448145510.1038/npp.2014.330 25518754
     [Google Scholar]
  150. FavaM. MemisogluA. ThaseM.E. Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: A randomized double-blind placebo-controlled trial.Am. J. Psychiatry2016173549950810.1176/appi.ajp.2015.15070921 26869247
     [Google Scholar]
  151. KanesS. ColquhounH. Gunduz-BruceH. Brexanolone (SAGE-547 injection) in post-partum depression: A randomised controlled trial.Lancet20173901009348048910.1016/S0140‑6736(17)31264‑3 28619476
     [Google Scholar]
  152. ColleR. de LarminatD. RotenbergS. Pioglitazone could induce remission in major depression: A meta-analysis.Neuropsychiatr. Dis. Treat.20161391610.2147/NDT.S121149 28031713
     [Google Scholar]
  153. DrevetsW.C. ZarateC.A.Jr FureyM.L. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: A review.Biol. Psychiatry201373121156116310.1016/j.biopsych.2012.09.031 23200525
     [Google Scholar]
  154. FureyM.L. PietriniP. HaxbyJ.V. DrevetsW.C. Selective effects of cholinergic modulation on task performance during selective attention.Neuropsychopharmacology200833491392310.1038/sj.npp.1301461 17534379
     [Google Scholar]
  155. BzdokD. Meyer-LindenbergA. Machine learning for precision psychiatry: Opportunities and challenges.Biol. Psychiatry Cogn. Neurosci. Neuroimaging20183322323010.1016/j.bpsc.2017.11.007 29486863
     [Google Scholar]
  156. ShatteA.B.R. HutchinsonD.M. TeagueS.J. Machine learning in mental health: A scoping review of methods and applications.Psychol. Med.20194991426144810.1017/S0033291719000151 30744717
     [Google Scholar]
  157. JoshiJ. GoeckeR. AlghowinemS. Multimodal assistive technologies for depression diagnosis and monitoring.J. Multimodal User Interfaces20137321722810.1007/s12193‑013‑0123‑2
     [Google Scholar]
  158. ZhuY. ShangY. ShaoZ. GuoG. Automated depression diagnosis based on deep networks to encode facial appearance and dynamics.IEEE Trans. Affect. Comput.20189457858410.1109/TAFFC.2017.2650899
     [Google Scholar]
  159. HallionL.S. RuscioA.M. A meta-analysis of the effect of cognitive bias modification on anxiety and depression.Psychol. Bull.2011137694095810.1037/a0024355 21728399
     [Google Scholar]
  160. PowerM. DalgleishT. Cognition and emotion: From order to disorder.Psychology press201510.4324/9781315708744
     [Google Scholar]
  161. McCarthyD.M. PedersenS.L. ThompsenD.M. LeutyM.E. Development of a measure of drinking and driving expectancies for youth.Psychol. Assess.200618215516410.1037/1040‑3590.18.2.155 16768591
     [Google Scholar]
  162. SaracinoR.M. ChamH. RosenfeldB. NelsonC.J. Confirmatory factor analysis of the Center for Epidemiologic Studies Depression Scale in oncology with examination of invariance between younger and older patients.Eur. J. Psychol. Assess.201836222923610.1027/1015‑5759/a000510 32684745
     [Google Scholar]
  163. DevlinN.J. BrooksR. EQ-5D and the EuroQol group: Past, present and future.Appl. Health Econ. Health Policy201715212713710.1007/s40258‑017‑0310‑5 28194657
     [Google Scholar]
  164. TrajkovićG. StarčevićV. LatasM. Reliability of the hamilton rating scale for depression: A meta-analysis over a period of 49 years.Psychiatry Res.201118911910.1016/j.psychres.2010.12.007 21276619
     [Google Scholar]
  165. DavidsonJ. TurnbullC.D. StricklandR. MillerR. GravesK. The montgomery-åsberg depression scale: Reliability and validity.Acta Psychiatr. Scand.198673554454810.1111/j.1600‑0447.1986.tb02723.x 3751660
     [Google Scholar]
  166. D’ZurillaT.J. NezuA.M. Maydeu-OlivaresA. Social problem-solving inventory-revised.APA PsycNet.2017Available From: https://psycnet.apa.org/doiLanding?doi=10.1037%2Ft05068-000 10.1037/t05068‑000
     [Google Scholar]
  167. AltmannR.A. ReynoldsC.R. KamphausR.W. VannestK.J. BASC-3.Encyclopedia of Clinical Neuropsychology.ChamSpringer201810.1007/978‑3‑319‑56782‑2_1524‑2
     [Google Scholar]
  168. SunS. WangS. The children’s depression inventory in worldwide child development research: A reliability generalization study.J. Child Fam. Stud.20152482352236310.1007/s10826‑014‑0038‑x
     [Google Scholar]
  169. NeufeldE. O’RourkeN. DonnellyM. Enhanced measurement sensitivity of hopeless ideation among older adults at risk of self-harm: Reliability and validity of Likert-type responses to the Beck Hopelessness Scale.Aging Ment. Health201014675275610.1080/13607860903421052 20686984
     [Google Scholar]
  170. RushA.J. TrivediM.H. IbrahimH.M. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression.Biol. Psychiatry200354557358310.1016/S0006‑3223(02)01866‑8 12946886
     [Google Scholar]
/content/journals/cpsp/10.2174/2211556011666230707122341
Loading
A Comprehensive Review on the Neuropharmacological Effects of Antidepressants in Various Prospects
Current Psychopharmacology 12, E070723218522 (2024); https://doi.org/10.2174/2211556011666230707122341
/content/journals/cpsp/10.2174/2211556011666230707122341
/content/journals/cpsp/10.2174/2211556011666230707122341
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): 5-HT-mediated neurotransmission; antidepressant drugs; behavioural analytic perspective; Depression; disabling illness; transdermal

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test